Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.79 |
| ▸ | MGLL | Q99685 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1714400 | 0.91 | PTGDR2 (0.90) | PTGDR2MGLLMAPT | |
| SCHEMBL1713709 | 0.87 | PTGDR2 (0.83) | PTGDR2SMN1; SMN2 | |
| SCHEMBL1713752 | 0.87 | PTGDR2 (0.83) | PTGDR2MGLL | |
| SCHEMBL1714022 | 0.86 | PTGDR2 (0.80) | PTGDR2SMN1; SMN2 | |
| SCHEMBL1713882 | 0.86 | PTGDR2 (0.57) | PTGDR2CNR1F10MAPTSMN1; SMN2 | |
| SCHEMBL1714179 | 0.85 | PTGDR2 (0.92) | PTGDR2 | |
| SCHEMBL13800250 | 0.85 | PTGDR2 (0.56) | PTGDR2CNR1AKR1B1MAPTSMN1; SMN2 | |
| SCHEMBL13800214 | 0.84 | PTGDR2 (0.88) | PTGDR2 | |
| SCHEMBL27833964 | 0.84 | PTGDR2 (0.55) | PTGDR2CNR1F10MAPTSMN1; SMN2 | |
| SCHEMBL13800220 | 0.81 | PTGDR2 (0.81) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524715-B2 | Phenoxyacetic acid derivatives useful for treating respiratory diseases | ASTRAZENECA AB (SE) | 2013-09-03 | — | — | US | claimed |
| EP-1817282-B1 | PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2011-07-20 | — | — | EP | claimed |
| US-20090149448-A1 | Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | claimed |
| EP-1817282-A1 | PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES | AstraZeneca AB (SE) | 2007-08-15 | — | — | EP | claimed |
| WO-2006056752-A1 | PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | WO | claimed |
| US-8524715-B2 | Phenoxyacetic acid derivatives useful for treating respiratory diseases | ASTRAZENECA AB (SE) | 2013-09-03 | — | — | US | disclosed |
| EP-1817282-B1 | PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2011-07-20 | — | — | EP | disclosed |
| US-20090149448-A1 | Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
| EP-1817282-A1 | PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES | AstraZeneca AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006056752-A1 | PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149448-A1 | Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases | PAOX, PCCA, PAH | PTGDR2 236/4885MGLL 1505/4885CNR1 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.